Loading
Spyre Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Souza Marcio, was filed 25 Aug 2022.
Insider Decl.
200
Thresholds
n/a
Buy Volume
€11M
48 ops. · all time
Sell Volume
€382M
92 ops. · all time
Who traded when
BuySaleCameron Turtle34 sales
Scott L. Burrows25 sales
Heidy King-Jones10 sales
Sloan Sheldon8 sales
Albers Jeffrey W.4 sales
Fairmount Funds Management LLC1 sale
+1 other insider
Since the insiders bought
- +2.5%Entry US$12.95 · Close at T+365 US$13.27
- -81.1%Entry US$18.48 · Close at T+365 US$3.50
- -88.0%Entry US$62.75 · Close at T+365 US$7.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Spyre Therapeutics, Inc. Strong Buy (bullish), based on 14 analysts. Average price target: US$119.29.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$84.72
Analyst consensus
14 analystsStrong buy
US$97.00Target US$119.29(+41%)US$130.00
Income statement
EBITDA-US$219.6M
Net income-US$155.2M0.0% margin
Valuation
PER (forward)-24.1x
P/Book7.8x
Beta3.11
Balance sheet & cash
Market capUS$7.9B
Free Cash Flow-US$169.3M
Profitability & ownership
ROE-23.0%
ROA-19.8%
% insiders1.6%
% institutions107.5%
Last declaration on 2 October 2026
Declarations200 total
28,933 shares@ US$14.500.0057% mcap7.1% of flowCommon StockSEC:0001636282-26-000119:0
400 shares@ US$89.240.0005% mcap0.6% of flowCommon StockSEC:0001636282-26-000119:1
16,605 shares@ US$90.350.020% mcap25.5% of flowCommon StockSEC:0001636282-26-000119:2
7,228 shares@ US$91.350.0089% mcap11.2% of flowCommon StockSEC:0001636282-26-000119:3
2,100 shares@ US$92.700.0026% mcap3.3% of flowCommon StockSEC:0001636282-26-000119:4
2,600 shares@ US$93.460.0033% mcap4.1% of flowCommon StockSEC:0001636282-26-000119:5
600 shares@ US$89.140.0007% mcap0.7% of flowCommon StockSEC:0001636282-26-000118:0
2,683 shares@ US$90.100.0033% mcap3.3% of flowCommon StockSEC:0001636282-26-000118:1
2,638 shares@ US$91.490.0033% mcap3.3% of flowCommon StockSEC:0001636282-26-000118:2
3,989 shares@ US$92.310.0050% mcap5.0% of flowCommon StockSEC:0001636282-26-000118:3
4,990 shares@ US$93.370.0063% mcap6.3% of flowCommon StockSEC:0001636282-26-000118:4
100 shares@ US$93.910.0001% mcap0.1% of flowCommon StockSEC:0001636282-26-000118:5
17,500 shares@ US$14.500.0034% mcap3.1% of flowCommon StockSEC:0001636282-26-000117:0
17,500 shares@ US$89.890.021% mcap19.1% of flowCommon StockSEC:0001636282-26-000117:1
7,500 shares@ US$14.500.0015% mcap1.3% of flowCommon StockSEC:0001636282-26-000117:2
600 shares@ US$89.070.0007% mcap0.6% of flowCommon StockSEC:0001636282-26-000117:3
1,500 shares@ US$90.270.0018% mcap1.6% of flowCommon StockSEC:0001636282-26-000117:4
2,100 shares@ US$91.920.0026% mcap2.3% of flowCommon StockSEC:0001636282-26-000117:5
3,071 shares@ US$92.950.0038% mcap3.5% of flowCommon StockSEC:0001636282-26-000117:6
229 shares@ US$93.570.0003% mcap0.3% of flowCommon StockSEC:0001636282-26-000117:7
29,335 shares@ US$89.030.035% mcap100.0% of flowCommonSEC144:0001950047-26-009971
45,000 shares@ US$89.030.053% mcap50.2% of flowCommonSEC144:0001950047-26-009978
17,500 shares@ US$89.89470.021% mcap54.7% of flowCommonSEC144:0001950047-26-009876
7,500 shares@ US$14.500.0014% mcap1.9% of flowCommon StockSEC:0001636282-26-000109:0
900 shares@ US$86.250.0010% mcap1.4% of flowCommon StockSEC:0001636282-26-000109:1
25 of 200 declarations
About Spyre Therapeutics, Inc.
On April 12, 2016, 4 insiders at Spyre Therapeutics, Inc. filed purchases for EUR 7,176,120 in total, including EUR 4,391,750 for Eli & Co Lilly and EUR 2,635,050 for Novartis Bioventures Ltd, both filed as holders of more than 10%. Anthony G. Quinn, President & CEO, bought EUR 716,050 on April 30, 2020 and totals 25 purchases among 36 filings.
The flow later tilted to the sales side, concentrated in 2026, a year that holds 105 of the 200 filings. Fairmount Funds Management LLC, filed as a director, sold EUR 351,208,032 on June 23, 2026, the day after a EUR 1,750,220 sale by director Michael Thomas Henderson. Scott L. Burrows (Chief Financial Officer) sold EUR 1,406,504 on September 2, 2026.
Read moreShow less
In all, 92 sales weigh EUR 381,918,597 (median EUR 215,780), against 48 purchases worth EUR 10,778,504 (median EUR 42,513), or 34% purchases. For the 47 purchases tracked at 90 days, the stored median is 1.4% (51% of results positive): recorded past results, not a forecast. Valuation: USD 7.9 billion; the last twelve months hold 109 filings, 81 of them sales.
